Healthcare & Eldercare 2026

AI robots in healthcare:
what works, at what scale

Surgical robots are proven at scale. Companion robots have clinical evidence. Rehabilitation exoskeletons are insurance-covered. General-purpose eldercare humanoids: pilots only, mostly Japan.

Last updated: July 2026

9,000+
Da Vinci surgical systems installed
2M+ procedures per year
$10.4B
Social/companion robot market 2026
CAGR 31%; $40.2B by 2031
37.85%
of companion robot revenue from healthcare
Largest single segment
140+
Hospitals using Aethon TUG logistics robots
FDA cleared for medication transport

Four sub-sectors

Healthcare robotics by category

Surgical Robotics

PROVEN AT SCALE

The most mature segment. Surgeon-controlled precision systems with FDA clearance and decade-long clinical evidence.

Key reference: Da Vinci (Intuitive Surgical)
9,000+ systems installed globally. 2M+ procedures per year. FDA cleared. Not autonomous — surgeon-controlled.
Da Vinci Xi / 5
Intuitive Surgical
9,000+ systems, 2M+ procedures/yr, used in 70+ countries
The category-defining product. Surgeon controls all movements — the system translates and scales for precision, removes hand tremor.
Hugo RAS
Medtronic
CE marked, expanding global footprint
Lower cost alternative targeting hospitals outside Da Vinci reach.
Versius
CMR Surgical
UK-developed, deployed in EU/Asia
Modular, compact design for smaller surgical suites.
Available now in major hospitals

Rehabilitation Robotics

INSURANCE-COVERED (SELECT MARKETS)

Exoskeletons and gait training systems for stroke and spinal cord injury rehabilitation. Some covered by insurance.

Key reference: Ekso Bionics EksoNR / Hocoma Lokomat
EksoNR: FDA cleared for stroke and acquired brain injury rehab. Lokomat: deployed in 1,500+ clinics globally.
EksoNR
Ekso Bionics
FDA 510(k) cleared, used in 300+ rehab centers
Exoskeleton for stroke and SCI. Insurance-covered in select US markets.
Lokomat
Hocoma
1,500+ deployed globally, 25+ years of clinical data
Robotic gait therapy. Strong evidence base for stroke rehabilitation.
Fourier GR-3
Fourier Intelligence
Partnerships: ETH Zurich, CMU
Next-gen rehab/care platform. GR-3 (not GR-2) designed for clinical and care contexts.
Available in rehab hospitals, some insurance coverage

Hospital Logistics

DEPLOYED IN 140+ HOSPITALS

Autonomous material transport within hospitals — medications, linens, waste, lab samples. Frees staff from non-clinical tasks.

Key reference: Aethon TUG
Deployed in 140+ hospitals. Autonomous navigation through corridors and elevators. FDA 510(k) for medication transport.
TUG
Aethon (Diligent Robotics)
140+ hospitals, FDA cleared for meds transport
The most deployed hospital logistics robot. Handles pharmacy, linen, and waste routes.
Moxi
Diligent Robotics
Deployed at 20+ hospital systems
Fetch-and-deliver for nurses — supplies, PPE, specimens. Reduces nurse non-clinical tasks.
Available now, scaled deployment

Companion & Social Robots

CLINICAL EVIDENCE FOR DEMENTIA

Therapeutic and social robots for elderly and cognitively impaired patients. PARO has the strongest evidence base.

Key reference: PARO (National Institute of AIST, Japan)
$6,000 per unit. Peer-reviewed evidence for dementia patients: reduced agitation, improved mood, decreased medication use.
PARO
AIST (Japan)
Deployed in Japan, US, EU. Multiple peer-reviewed RCT studies.
Therapeutic robot seal. The most evidence-based social robot available. Specialist tool for dementia care — not a general companion.
LOVOT
Groove X (Japan)
Consumer companion robot, $3,000+
Designed for emotional connection. Used in eldercare facilities and consumer homes in Japan.
Available now, specialist use cases

Regulatory framework

How healthcare robots get cleared

United States (FDA)

510(k) clearance or PMA

Surgical robots and rehabilitation devices require 510(k) or PMA. Companion and logistics robots face lower barriers. FDA has not cleared fully autonomous surgical AI.

FDA 21 CFR Part 820

European Union

EU MDR (Medical Device Regulation)

Medical device robots fall under EU MDR since May 2021. Class IIa and above require Notified Body assessment. IEC 80601-2-77 for robot-assisted surgery recognized May 2025.

EU MDR 2017/745 + IEC 80601-2-77

Japan

PMDA + METI subsidies

Japan has the most progressive regulatory environment for care robots. METI actively subsidizes eldercare robot adoption. PARO, LOVOT, and multiple humanoid pilots cleared here first.

PMDA; Robot Strategy 2015 framework

Japan as leading market

Why Japan is the world's test lab for eldercare robots

Japan does not lead in eldercare robotics because it is more innovative. It leads because it has no alternative. The demographic pressure is unlike anywhere else on earth.

The numbers

40%
of Japan's population will be 65+ by 2060
380,000
current shortfall of care workers
¥20B+
government investment in care robotics since 2015
13
priority care robot categories defined by METI

What Japan has proven

  • —PARO reduces medication use in dementia patients — peer-reviewed evidence from Japanese clinical trials before US/EU adoption
  • —Robotic lift-assist devices (HAL, Cyberdyne) prevent caregiver injury — the most consistent ROI in care robotics
  • —Social robots do not replace human caregivers — they supplement by handling structured interaction tasks
  • —Adoption requires caregiver buy-in — facilities that imposed robots without training saw abandonment within 3 months
  • —General-purpose eldercare humanoids: pilots only as of mid-2026, even in Japan. Not at scale.

Now vs coming

Available today vs. what is still in development

Available now (clinically)

Surgical assistance robots
Da Vinci, Versius, Hugo — FDA/CE cleared, hospital-deployed
Rehabilitation exoskeletons
EksoNR, Lokomat — cleared, some insurance coverage
Hospital logistics robots
TUG, Moxi — 140+ hospitals, autonomous material transport
Dementia companion robots
PARO — peer-reviewed evidence, specialist use, $6,000
Robotic lift-assist
HAL (Cyberdyne), exosuits — Japan-first, EU clearance expanding

Still in development / pilots

General-purpose eldercare humanoids
Pilots in Japan only. No scaled deployment. 2028-2032 earliest for clinical use.
Autonomous surgical AI
Research stage. FDA has not cleared autonomous surgical decision-making.
AI-driven diagnostics robots
Teleoperated diagnostic robots exist; autonomous versions in trials.
Medication dispensing humanoids
Logistics robots handle transport; humanoid dispensing at bedside is pilot-stage.
Home care robots
No certified home-care humanoid available. Japan pilots ongoing. 5+ years from consumer availability.

FAQ

Common questions

Are surgical robots autonomous?

No. The Da Vinci system — 9,000+ systems, 2M+ procedures per year — is surgeon-controlled. The robot amplifies precision and removes hand tremor but executes the surgeon's movements. Fully autonomous surgical AI does not have FDA clearance for independent operation in 2026.

What companion robots exist for elderly people?

PARO is the most evidence-based companion robot for elderly care — a therapeutic robot seal at $6,000, validated in peer-reviewed studies for dementia patients. It reduces agitation, improves mood, and decreases medication use. It is a specialist clinical tool, not a general companion.

Is Japan really leading on eldercare robots?

Yes. Japan faces the most acute elder care labor shortage globally: 40% of the population will be 65+ by 2060, with a current shortfall of 380,000 care workers. The government subsidizes eldercare robot adoption, making Japan the primary testing ground for care robotics.

What is the regulatory process for healthcare robots?

In the US: FDA 510(k) clearance or PMA for surgical and rehabilitation devices. In the EU: EU MDR for medical device robots; IEC 80601-2-77 for robot-assisted surgery recognized May 2025. Japan has the most progressive regulatory environment, with METI actively subsidizing adoption.

← All applicationsManufacturing & Logistics →